Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion type Assertion NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_head.
- NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion description "[In contrast, administration of the selective progesterone receptor antagonist reduced overexpression of Pmp22 and improved the CMT phenotype, without obvious side effects, in wild-type or transgenic rats.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_provenance.
- NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion evidence source_evidence_literature NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_provenance.
- NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion SIO_000772 14608378 NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_provenance.
- NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion wasDerivedFrom befree-2016 NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_provenance.
- NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_assertion wasGeneratedBy ECO_0000203 NP419994.RACODi82bv9pVNv6__JZabt-QHPIBrXsGCYpjfXn9Xeio130_provenance.